• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For March 7, 2023

    3/7/23 8:37:46 AM ET
    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Real Estate
    Finance
    Managed Health Care
    Health Care
    Get the next $AFCG alert in real time by email

    Companies Reporting Before The Bell

    • Cohen & Co (AMEX:COHN) is likely to report earnings for its fourth quarter.

    • Xtant Medical Holdings (AMEX:XTNT) is expected to report earnings for its fourth quarter.

    • Ferguson (NYSE:FERG) is likely to report quarterly earnings at $2.01 per share on revenue of $6.84 billion.

    • Zevra Therapeutics (NASDAQ:ZVRA) is likely to report quarterly loss at $0.17 per share on revenue of $3.20 million.

    • Westwater Resources (AMEX:WWR) is estimated to report earnings for its fourth quarter.

    • Voyager Therapeutics (NASDAQ:VYGR) is estimated to report quarterly loss at $0.55 per share on revenue of $4.19 million.

    • Seres Therapeutics (NASDAQ:MCRB) is projected to report quarterly loss at $0.46 per share on revenue of $6.00 million.

    • Alaunos Therapeutics (NASDAQ:TCRT) is likely to report earnings for its fourth quarter.

    • Dole (NYSE:DOLE) is expected to report quarterly earnings at $0.05 per share on revenue of $2.26 billion.

    • OptiNose (NASDAQ:OPTN) is likely to report quarterly loss at $0.17 per share on revenue of $20.69 million.

    • CorEnergy Infr Trust (NYSE:CORR) is projected to report earnings for its fourth quarter.

    • AFC Gamma (NASDAQ:AFCG) is expected to report quarterly earnings at $0.58 per share on revenue of $18.37 million.

    • Vivid Seats (NASDAQ:SEAT) is expected to report quarterly earnings at $0.12 per share on revenue of $154.51 million.

    • Tremor Intl (NASDAQ:TRMR) is projected to report quarterly earnings at $0.37 per share on revenue of $103.13 million.

    • Thor Industries (NYSE:THO) is projected to report quarterly earnings at $1.13 per share on revenue of $2.49 billion.

    • Sophia Genetics (NASDAQ:SOPH) is likely to report earnings for its fourth quarter.

    • Canaan (NASDAQ:CAN) is expected to report quarterly loss at $0.17 per share on revenue of $43.59 million.

    • Enfusion (NYSE:ENFN) is expected to report quarterly earnings at $0.03 per share on revenue of $40.00 million.

    • Ranger Energy Services (NYSE:RNGR) is likely to report quarterly earnings at $0.36 per share on revenue of $171.20 million.

    • Neuronetics (NASDAQ:STIM) is projected to report quarterly loss at $0.38 per share on revenue of $16.82 million.

    • Dick's Sporting Goods (NYSE:DKS) is likely to report quarterly earnings at $2.87 per share on revenue of $2.

    • 908 Devices (NASDAQ:MASS) is expected to report quarterly loss at $0.26 per share on revenue of $11.43 million.

    • Autolus Therapeutics (NASDAQ:AUTL) is projected to report quarterly loss at $0.27 per share on revenue of $3.20 million.

    • Latham Group (NASDAQ:SWIM) is projected to report quarterly loss at $0.07 per share on revenue of $101.66 million.

    • Landsea Homes (NASDAQ:LSEA) is likely to report quarterly earnings at $0.75 per share on revenue of $441.48 million.

    • Verona Pharma (NASDAQ:VRNA) is estimated to report quarterly loss at $0.10 per share on revenue of $3.57 million.

    • First Watch Restaurant Gr (NASDAQ:FWRG) is likely to report quarterly earnings at $0.02 per share on revenue of $187.25 million.

    • Squarespace (NYSE:SQSP) is estimated to report quarterly earnings at $0.11 per share on revenue of $222.11 million.

    • Sea (NYSE:SE) is estimated to report quarterly loss at $0.77 per share on revenue of $3.12 billion.

    • BlackSky Technology (NYSE:BKSY) is likely to report quarterly loss at $0.16 per share on revenue of $19.62 million.

    • Perfect (NYSE:PERF) is projected to report quarterly earnings at $0.02 per share on revenue of $15.34 million.

    • Wag Group (NASDAQ:PET) is expected to report earnings for its fourth quarter.

    • ESAB (NYSE:ESAB) is expected to report quarterly earnings at $0.88 per share on revenue of $586.25 million.

    Companies Reporting After The Bell

    • Cumberland (NASDAQ:CPIX) is estimated to report earnings for its fourth quarter.

    • Red Cat Holdings (NASDAQ:RCAT) is expected to report quarterly loss at $0.09 per share on revenue of $2.65 million.

    • Momentus (NASDAQ:MNTS) is expected to report quarterly loss at $0.28 per share on revenue of $500 thousand.

    • Cherry Hill Mortgage (NYSE:CHMI) is projected to report quarterly earnings at $0.27 per share on revenue of $5.10 million.

    • Full House Resorts (NASDAQ:FLL) is likely to report quarterly loss at $0.11 per share on revenue of $39.53 million.

    • CPS Technologies (NASDAQ:CPSH) is projected to report earnings for its fourth quarter.

    • W&T Offshore (NYSE:WTI) is estimated to report quarterly earnings at $0.06 per share on revenue of $182.38 million.

    • Rigel Pharmaceuticals (NASDAQ:RIGL) is expected to report quarterly loss at $0.11 per share on revenue of $27.97 million.

    • Durect (NASDAQ:DRRX) is expected to report quarterly loss at $0.55 per share on revenue of $3.48 million.

    • Intellicheck (NASDAQ:IDN) is likely to report quarterly loss at $0.03 per share on revenue of $4.60 million.

    • Fuel Tech (NASDAQ:FTEK) is projected to report quarterly loss at $0.03 per share on revenue of $6.38 million.

    • Treace Medical Concepts (NASDAQ:TMCI) is estimated to report quarterly loss at $0.14 per share on revenue of $44.40 million.

    • Invesco National AMT-Free Municipal Bond ETFo (NYSE:PZA) is estimated to report earnings for its fourth quarter.

    • VanEck Energy Income ETF (NYSE:EINC) is projected to report earnings for its fourth quarter.

    • Maxeon Solar Technologies (NASDAQ:MAXN) is likely to report earnings for its fourth quarter.

    • TDCX (NYSE:TDCX) is projected to report quarterly earnings at $0.14 per share on revenue of $135.63 million.

    • Aquestive Therapeutics (NASDAQ:AQST) is likely to report quarterly loss at $0.23 per share on revenue of $10.42 million.

    • Couchbase (NASDAQ:BASE) is expected to report quarterly loss at $0.34 per share on revenue of $38.26 million.

    • CarParts.com (NASDAQ:PRTS) is expected to report quarterly loss at $0.11 per share on revenue of $151.18 million.

    • Marinus Pharma (NASDAQ:MRNS) is expected to report quarterly loss at $0.70 per share on revenue of $5.27 million.

    • Arlo Technologies (NYSE:ARLO) is expected to report quarterly loss at $0.10 per share on revenue of $107.44 million.

    • Forian (NASDAQ:FORA) is expected to report quarterly loss at $0.27 per share on revenue of $27.00 million.

    • Ero Copper (NYSE:ERO) is likely to report quarterly earnings at $0.40 per share on revenue of $154.69 million.

    • Allied Motion (NASDAQ:AMOT) is estimated to report quarterly earnings at $0.50 per share on revenue of $126.17 million.

    • Yext (NYSE:YEXT) is likely to report quarterly earnings at $0.03 per share on revenue of $100.39 million.

    • Synchronoss Technologies (NASDAQ:SNCR) is expected to report quarterly earnings at $0.06 per share on revenue of $65.23 million.

    • Invesco DWA Industrials Momentum ETF (NASDAQ:PRN) is projected to report quarterly loss at $0.50 per share on revenue of $3.97 million.

    • Profound Medical (NASDAQ:PROF) is estimated to report quarterly loss at $0.36 per share on revenue of $2.72 million.

    • Agiliti (NYSE:AGTI) is estimated to report quarterly earnings at $0.17 per share on revenue of $272.74 million.

    • Cricut (NASDAQ:CRCT) is projected to report quarterly earnings at $0.06 per share on revenue of $241.40 million.

    • CrowdStrike Holdings (NASDAQ:CRWD) is expected to report quarterly earnings at $0.43 per share on revenue of $624.95 million.

    • Accelerate Diagnostics (NASDAQ:AXDX) is likely to report quarterly loss at $0.15 per share on revenue of $2.87 million.

    • Crescent Energy (NYSE:CRGY) is estimated to report quarterly earnings at $0.74 per share on revenue of $617.40 million.

    • SoundHound AI (NASDAQ:SOUN) is estimated to report quarterly loss at $0.17 per share on revenue of $8.74 million.

    • BSQUARE (NASDAQ:BSQR) is projected to report earnings for its fourth quarter.

    • PCTEL (NASDAQ:PCTI) is expected to report quarterly earnings at $0.16 per share on revenue of $26.00 million.

    • Stitch Fix (NASDAQ:SFIX) is likely to report quarterly loss at $0.32 per share on revenue of $393.57 million.

    • Harte-Hanks (NASDAQ:HHS) is projected to report quarterly earnings at $0.10 per share on revenue of $52.20 million.

    • Zymeworks (NASDAQ:ZYME) is estimated to report quarterly earnings at $3.12 per share on revenue of $214.33 million.

    • MasterBrand (NYSE:MBC) is projected to report quarterly earnings at $0.51 per share on revenue of $769.00 million.

    • Casey's General Stores (NASDAQ:CASY) is projected to report quarterly earnings at $1.60 per share on revenue of $3.59 billion.

    • Energy Vault Holdings (NYSE:NRGV) is projected to report quarterly loss at $0.15 per share on revenue of $65.45 million.

    • Akili (NASDAQ:AKLI) is likely to report quarterly loss at $0.30 per share on revenue of $80 thousand.

    • Weyco Group (NASDAQ:WEYS) is expected to report earnings for its fourth quarter.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFCG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFCG
    $AGTI
    $AKLI
    $AMOT

    CompanyDatePrice TargetRatingAnalyst
    Ero Copper Corp.
    $ERO
    2/9/2026Buy → Neutral
    BofA Securities
    Casey's General Stores Inc.
    $CASY
    1/21/2026Buy → Neutral
    Northcoast
    Casey's General Stores Inc.
    $CASY
    1/20/2026$730.00Outperform
    BNP Paribas Exane
    Ero Copper Corp.
    $ERO
    1/14/2026Hold → Buy
    Canaccord Genuity
    Thor Industries Inc.
    $THO
    1/13/2026$133.00Hold → Buy
    Loop Capital
    CrowdStrike Holdings Inc.
    $CRWD
    1/12/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    Crescent Energy Company
    $CRGY
    1/9/2026$10.00Market Perform
    BMO Capital Markets
    Casey's General Stores Inc.
    $CASY
    1/9/2026Buy
    BofA Securities
    More analyst ratings

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Castanon Moats Maria bought $166,398 worth of shares (300 units at $554.66), increasing direct ownership by 60% to 803 units (SEC Form 4)

    4 - CASEYS GENERAL STORES INC (0000726958) (Issuer)

    1/6/26 2:20:38 PM ET
    $CASY
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Director Tannenbaum Leonard M bought $76,250 worth of shares (25,000 units at $3.05), increasing direct ownership by 0.43% to 5,861,098 units (SEC Form 4)

    4 - Advanced Flower Capital Inc. (0001822523) (Issuer)

    12/15/25 4:29:58 PM ET
    $AFCG
    Real Estate
    Finance

    Director Tannenbaum Leonard M bought $128,520 worth of shares (44,000 units at $2.92), increasing direct ownership by 0.76% to 5,836,098 units (SEC Form 4)

    4 - Advanced Flower Capital Inc. (0001822523) (Issuer)

    12/10/25 4:55:33 PM ET
    $AFCG
    Real Estate
    Finance

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ero Copper downgraded by BofA Securities

    BofA Securities downgraded Ero Copper from Buy to Neutral

    2/9/26 7:00:02 AM ET
    $ERO
    Metal Mining
    Basic Materials

    Casey's General downgraded by Northcoast

    Northcoast downgraded Casey's General from Buy to Neutral

    1/21/26 8:51:47 AM ET
    $CASY
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    BNP Paribas Exane initiated coverage on Casey's General with a new price target

    BNP Paribas Exane initiated coverage of Casey's General with a rating of Outperform and set a new price target of $730.00

    1/20/26 8:17:04 AM ET
    $CASY
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

    For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

    4/26/23 6:04:21 PM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    SEC Filings

    View All

    Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    2/10/26 5:09:09 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Voyager Therapeutics Inc.

    144 - Voyager Therapeutics, Inc. (0001640266) (Subject)

    2/10/26 4:23:53 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MasterBrand Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MasterBrand, Inc. (0001941365) (Filer)

    2/10/26 4:08:32 PM ET
    $MBC
    Home Furnishings
    Consumer Discretionary

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SoundHound AI To Report 2025 Fourth Quarter and Full Year Financial Results, Host Conference Call and Webcast on February 26

    SANTA CLARA, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- SoundHound AI, Inc. (NASDAQ:SOUN), a global leader in voice and conversational AI, today announced that it will report its 2025 fourth quarter and full year financial results on Thursday, February 26, 2026 after market close. The company will host a conference call and webcast to review the results on the same day. Conference Call and Webcast Information Keyvan Mohajer, Co-Founder and CEO, and Nitesh Sharan, CFO, will host the conference call at 2:00 p.m. PT / 5:00 p.m. ET. A live audio webcast will be available at investors.soundhound.com and a replay will be available at the same location. If you wish to receive company email no

    2/10/26 4:10:00 PM ET
    $SOUN
    Computer Software: Prepackaged Software
    Technology

    MasterBrand Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter and full year net sales decreased 3.5% and increased 1.3% year-over-year to $644.6 million and $2.7 billion, respectively Fourth quarter and full year net (loss) income margin decreased 860 basis points and 370 basis points year-over-year to (6.5)% and 1.0%, respectively Fourth quarter and full year adjusted EBITDA margin1 decreased 580 basis points and 260 basis points year-over-year to 5.4% and 10.9%, respectively Fourth quarter and full year diluted (loss) earnings per share were $(0.33) and $0.21, compared to $0.11 and $0.96 in the prior year, respectively; fourth quarter and full year adjusted diluted (loss) earnings per share1 were $(0.02) and $0.91, compared

    2/10/26 4:05:00 PM ET
    $MBC
    Home Furnishings
    Consumer Discretionary

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Mcfarlane Neil F. converted options into 37,500 shares and sold $125,186 worth of shares (14,625 units at $8.56), increasing direct ownership by 6% to 387,225 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    2/10/26 4:49:28 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Ferguson Toby was granted 45,000 shares, increasing direct ownership by 32% to 183,914 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    2/10/26 4:33:26 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Carter Todd Alfred was granted 33,000 shares, increasing direct ownership by 27% to 156,718 units (SEC Form 4)

    4 - Voyager Therapeutics, Inc. (0001640266) (Issuer)

    2/10/26 4:32:54 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Leadership Updates

    Live Leadership Updates

    View All

    Arlo Technologies Announces Inducement Awards Under NYSE Rule 303A.08

    SAN JOSE, Calif., Feb. 4, 2026 /PRNewswire/ -- Arlo Technologies, Inc. (NYSE:ARLO), a leading smart home security brand, today announced that it had made equity grants to new employees under its 2018 Equity Incentive Plan in accordance with NYSE Rule 303A.08. On February 4, 2026, Arlo's Compensation and Human Capital Committee granted restricted stock units, or RSUs, to three new non-executive employees covering an aggregate of 17,380 shares of the Company's common stock as an inducement for such employees to join the Company. The RSUs vest annually in four equal annual instal

    2/4/26 6:19:00 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    Rigel Appoints Michael P. Miller to the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries. "Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board," said Raul Rodriguez, Rigel's president and CEO. "His extensive expertise in commercial execution and leadership will provide valuable insights as we execute on our transformational strategic plan, particularly our objectives of growing our current portfolio of medicines

    2/3/26 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eddyfi Technologies Announces Signing of Definitive Agreement to join ESAB

    QUEBEC CITY, Feb. 2, 2026 /CNW/ - Eddyfi Technologies, a global leader in advanced non-destructive testing and integrity management technologies and solutions, is pleased to announce that it has entered into a definitive agreement to join ESAB, a focused premier industrial compounder. The transaction, valued at US$1.45 billion or C$2.0 billion in cash for 100 percent of the outstanding shares of the company, is subject to customary regulatory approvals and closing conditions and is expected to close later in 2026. This announcement marks an important milestone following the sp

    2/2/26 1:07:00 PM ET
    $ESAB
    Industrial Machinery/Components
    Industrials

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Financials

    Live finance-specific insights

    View All

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SoundHound AI To Report 2025 Fourth Quarter and Full Year Financial Results, Host Conference Call and Webcast on February 26

    SANTA CLARA, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- SoundHound AI, Inc. (NASDAQ:SOUN), a global leader in voice and conversational AI, today announced that it will report its 2025 fourth quarter and full year financial results on Thursday, February 26, 2026 after market close. The company will host a conference call and webcast to review the results on the same day. Conference Call and Webcast Information Keyvan Mohajer, Co-Founder and CEO, and Nitesh Sharan, CFO, will host the conference call at 2:00 p.m. PT / 5:00 p.m. ET. A live audio webcast will be available at investors.soundhound.com and a replay will be available at the same location. If you wish to receive company email no

    2/10/26 4:10:00 PM ET
    $SOUN
    Computer Software: Prepackaged Software
    Technology

    MasterBrand Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth quarter and full year net sales decreased 3.5% and increased 1.3% year-over-year to $644.6 million and $2.7 billion, respectively Fourth quarter and full year net (loss) income margin decreased 860 basis points and 370 basis points year-over-year to (6.5)% and 1.0%, respectively Fourth quarter and full year adjusted EBITDA margin1 decreased 580 basis points and 260 basis points year-over-year to 5.4% and 10.9%, respectively Fourth quarter and full year diluted (loss) earnings per share were $(0.33) and $0.21, compared to $0.11 and $0.96 in the prior year, respectively; fourth quarter and full year adjusted diluted (loss) earnings per share1 were $(0.02) and $0.91, compared

    2/10/26 4:05:00 PM ET
    $MBC
    Home Furnishings
    Consumer Discretionary

    $AFCG
    $AGTI
    $AKLI
    $AMOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Landsea Homes Corporation

    SC 13G - Landsea Homes Corp (0001721386) (Subject)

    12/13/24 8:08:18 PM ET
    $LSEA
    Homebuilding
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Ranger Energy Services Inc.

    SC 13D/A - Ranger Energy Services, Inc. (0001699039) (Subject)

    12/12/24 6:49:54 PM ET
    $RNGR
    Oilfield Services/Equipment
    Energy